在2期试验中,贝克西卡赛林可减少患有罕见症的儿童的发作,并显示出持久的效果和安全性. Bexicaserin reduced seizures in children with rare epilepsy disorders, showing lasting results and safety in a Phase 2 trial.

隆德贝克报告了长期的积极的Bexicaserin2期数据,这些数据显示在PACIFIC试验及其延长期间,在患有罕见的,耐药的发育性和性脑病变 (DEE) 的儿童中,发作持续减少了60. 2%在18个月后和53. 7%在24个月后. Lundbeck reported positive long-term Phase 2 data for bexicaserin in children with rare, drug-resistant developmental and epileptic encephalopathies (DEEs), showing sustained seizure reduction—60.2% at 18 months and 53.7% at 24 months—during the PACIFIC trial and its extension. 治疗显示了一种有利的安全状况,药物相互作用最少,为一流治疗提供了潜力。 The treatment demonstrated a favorable safety profile with minimal drug interactions, offering potential for a first-in-class therapy. 致使严重发作和发育迟缓的DEE, 缺乏所有亚型的批准治疗方法, 让家庭几乎没有选择. DEEs, which cause severe seizures and developmental delays, lack approved treatments across all subtypes, leaving families with few options. 在2025年美国癫痫患者协会年会上介绍了结果。 Results were presented at the 2025 American Epilepsy Society Annual Meeting.